Truist raised the firm’s price target on HCA Healthcare (HCA) to $495 from $460 and keeps a Buy rating on the shares. The firm is bullish on HCA following Q3 results which came in ahead of consensus expectations on the top and bottom-lines, while FY25 guidance was raised to reflect increased supplemental payments and better core operational results, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare price target raised to $500 from $450 at Stephens
- HCA Healthcare price target raised to $482 from $449 at RBC Capital
- HCA Healthcare: Hold Rating Amid Policy Uncertainties and Volume Growth Concerns
- HCA Healthcare price target raised to $470 from $430 at BofA
- HCA Healthcare price target raised to $490 from $380 at TD Cowen